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Abstract
Background: Observational studies have reported conflicting results on the impact of mammography service
screening programmes on the advanced breast cancer rate (ABCR), a correlation that was firmly established in
randomized controlled trials. We reviewed and summarized studies of the effect of service screening programmes
in the European Union on ABCR and discussed their limitations.
Methods: The PubMed database was searched for English language studies published between 01-01-2000 and
01–06-2018. After inspection of titles and abstracts, 220 of the 8644 potentially eligible papers were considered
relevant. Their abstracts were reviewed by groups of two authors using predefined criteria. Fifty studies were selected
for full paper review, and 22 of these were eligible. A theoretical framework for their review was developed. Review
was performed using a ten-point checklist of the methodological caveats in the analysis of studies of ABCR and a
standardised assessment form designed to extract quantitative and qualitative information.
Results: Most of the evaluable studies support a reduction in ABCR following the introduction of screening. However,
all studies were challenged by issues of design and analysis which could at least potentially cause bias, and showed
considerable variation in the estimated effect. Problems were observed in duration of follow-up time, availability of
reliable reference ABCR, definition of advanced stage, temporal variation in the proportion of unknown-stage cancers,
and statistical approach.
Conclusions: We conclude that much of the current controversy on the impact of service screening programmes on
ABCR is due to observational data that were gathered and/or analysed with methodological approaches which could
not capture stage effects in full. Future research on this important early indicator of screening effectiveness should
focus on establishing consensus in the correct methodology.
Keywords: Breast cancer, Mammography, Screening, Advanced stage, Review
Background
A long follow-up is required to assess the impact of
mammography screening programmes on breast cancer
mortality. The advanced breast cancer incidence rate
(hereafter briefly referred to as advanced breast cancer
rate, ABCR) can potentially be used as an earlier indica-
tor of the effectiveness of a screening programme. More-
over, since tumour stage at diagnosis is independent of
treatment, except for neoadjuvant therapy, analysis of
trends in ABCR allows the effects of early detection to
be disentangled from those of improvements in treat-
ment [1]. The correlation between reductions in breast
cancer mortality and ABCR has been firmly established
on the basis of screening trials [2]. In a pooled analysis
of data from eight trials, the decrease in the risk of
advanced breast cancer and the decrease in the risk of
dying from the disease were approximately proportional
[1, 3]. It is clear that screening is associated with a re-
duction in the proportion of advanced stage cancers [4].
However, observational studies published over the last
15–20 years have yielded conflicting results on the asso-
ciation between the introduction of population-based
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service screening programmes and changes in ABCR, i.e.
the absolute incidence of advanced stage disease [3, 5].
Nevertheless, the evaluation of the change in the
incidence of advanced breast cancer cases is relevant in
service screening outcome research. An apparent lack of
this change has been considered by some as evidence of
the lack of mammography screening programmes’ effec-
tiveness [5–8].
The objectives of the current study were (a) to review
studies of the effect of mammography screening pro-
grammes in Europe on ABCR, and (b) to summarize
their limitations and the extent to which they contribute
to the evidence on screening effectiveness.
Methods
Search strategy and selection criteria
A systematic search of PubMed with the search terms
‘cancer stage’, ‘screening’, ‘breast cancer’, ‘incidence’, and
‘mammography’ was performed to identify papers
published from January 2000 until May 2013 (details in
Appendix) and later updated to June 2018. Only papers
in English evaluating European programmes were
reviewed. The search strategy was built using 7 key
papers [9–15].
Abstracts from the papers identified were reviewed by
two from a group of four reviewers (MB, PA, SM, LB)
and papers for full review were selected using the follo-
wing general criteria: (a) the study represented original
data and estimated the impact of a current regional or
national population-based screening programme in
Europe; (b) definition of advanced disease was based on
breast cancer size, nodal status and/or stage at diagnosis
of breast cancer; (c) the analysis included at least some
of the age groups between 50 and 69; (d) the study used
an observational research design comparing rates or pro-
portions of advanced stage cancers; and (e) an uninvited
and/or unscreened control population was available.
This included the pre-screening years for the population
targeted for screening in the study. Comparisons only of
attenders vs non-attenders were not included. We focused
the review on European programmes to add evidence on
advanced breast cancer to the European balance sheet of
benefits and harms as an outcome to the work of the
Euroscreen reviews of observational mortality studies [16].
Definition of advanced breast cancer
Tumour staging criteria vary across studies and even
studies using the UICC TNM classification [17] show
little agreement in their definition of advanced breast
cancer. Theoretically, the benefit of screening is limited
to screen-detected cases, either earlier within the same
stage or at an earlier stage. However, using stage in itself
has a disadvantage due to the stage migration bias
caused by the introduction of sentinel lymph node
dissection [18] and by changes in coding and classifica-
tion practices [19]. In this respect, using only the pT in-
formation as a proxy for the diameter of the lesion is the
most direct link to radiological detection and less influ-
enced by trends in missing data and changes in coding
and classification practices, even though it cannot show
within-stage shifts in diameter. It is therefore the least
biased option to define advanced breast cancer detec-
tion. Tumour size (measured in mm), even though put
forward by some authors as an indicator of diagnostic
anticipation [20], has never been confirmed as such and
is often inaccurate since pathologists tend to round to
the nearest multiple of five (terminal digit preference
bias) [21].
Theoretical framework and checklist
We designed an assessment form to extract detailed
quantitative and qualitative information, the study
design, completeness of information and results from
the selected papers in a standardized fashion.
The expected effect of mammography service screen-
ing programmes on ABCR is best understood looking at
the randomized controlled trials (RCTs) as a reference,
as previously described [1–3]. Based on the RCTs, the
ABCR in the population invited to screening, usually
from age 50, is expected to remain stable or slightly
increase when the programme starts. The increasing in-
cidence, in comparison with the prescreening incidence
rate, is due to the intra-stage shift. This means that
screening will detect advanced cancer cases earlier, but
still within the same stage as in the absence of screening.
After the prevalence screening, assuming a 100% sensi-
tivity, the advanced cancer cases will be diagnosed as
interval cancers, if fast growing, or are expected to be
detected earlier at subsequent rounds. For this reason,
the expectation is a reduction of the ABCR 2–3 years
after the start (Fig. 1). The advanced cancer cases that
are detected earlier through screening than they would
have been in the situation without screening are the
ones which should benefit. The ABCR should thus de-
crease from the time of prevalent screening (time 0) to a
lower level than the expected, reaching a plateau after a
few years, because screening will move diagnoses of
breast cancer cases forward in time as long as the
programme continues. If screening stops, e.g. at 65 or
69 years in most European screening programmes, the
ABCR is expected to increase again, rising after some
years to the prescreening level (age-specific) .
In order to discern this pattern of occurrence, the
ABCR with or without screening will be best observed
in a study where individual women are followed over
time, and an unconfounded comparison of screening
with non-screening incidence is available. In order to as-
sess the extent to which studies achieve or approximate
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this ideal situation, we developed a ten-point checklist of
the main methodological issues with which such studies
of ABCR have to contend, logically derived from the
above described theoretical framework (Table 1). The
checklist is based on epidemiological principles of obser-
vational studies as applied to screening [22] and previous
research experience, including knowledge of the relevant
literature from outside of Europe [6, 7, 23–26] and find-
ings of the Euroscreen reviews of observational mortality
studies (trend studies, incidence-based mortality studies,
and case-control studies) [27, 28]. The methodological
issues identified using the ten-point checklist, their
definitions, and their consequences on design, likely ac-
curacy, and results of studies are presented in Table 1.
This in turn highlights the main potential departures of
studies from the ideal design of a study of the temporal
association between mammography screening pro-
grammes and incidence of advanced stage breast cancer,
and indicates the major issues of interpretation of the
results.
The checklist items included: 4 complications related
to the timescale of screening introduction, periods of ex-
posure and observation, and transient prevalence screen
effects; 3 to endpoint definition, stage migration and
completeness of stage data; 1 to difficulties of formal in-
ference; and 2 to the inevitable problem of incomplete
information on what the incidence of breast cancer
overall and of advanced disease would have been in the
absence of the screening programme.
Presentation of results
Due to the heterogeneity in methodology and endpoints
used in the studies, no attempt was made to produce a
pooled estimate of the effect of screening on ABCR. In-
stead, we reported details of methods and results of each
study individually in Additional file 1: Table S1. We
looked for data on screening coverage and attendance
rates from other sources as well, if the selected study did
not provide that information.
Results
Selection of studies
The search strategy identified 8644 English-language pa-
pers of which 220 were considered relevant based on title
and abstract (Fig. 2), including both studies of incidence
rates and those of proportions of advanced cancers.
Based on the selection criteria, 38 studies were
included, and a further 24 were identified as possible in-
clusions. For the latter group, full papers were assessed
by two different reviewers, with arbitration by a third
(SD) where necessary, which resulted in the inclusion of
4 studies. In addition, the abstract of one paper sug-
gested by a co-author was assessed and included for re-
view. In total, after adding the 7 key papers, 50 studies
were included for full paper review by the two reviewers
who had not assessed the abstracts. We also manually
searched the reference lists of these papers and identi-
fied 10 references that fulfilled the inclusion criteria but
had not been identified by the search strategy. Review of
the full papers for these references resulted in the
inclusion of an additional 5 studies. Differences between
reviews were resolved through consensus by all four re-
viewers. Of the 60 full paper reviews in total, 22 studies
were found eligible for inclusion in a comparison of
incidence rates as the outcome measure [8, 12–15, 19,
29–44]. A further 9 studies were comparisons of propor-
tions of advanced cancers and not included in the
current review. Of the 29 papers excluded, 21 lacked a
suitable control group, 3 were not related to
population-based screening and 5 were excluded for
Fig. 1 Expected effect of mammography service screening on the occurrence of advanced breast cancer, illustrated by Fig. 2, right panel, from
Foca et al. [15]. Ratios with 95% confidence intervals are illustrated between the observed and expected age-standardised incidence rates of
breast cancer per 100,000 women according to a 2-year screening period (ages 55 to 74 years). pT indicates pathologic tumour classification
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Table 1 Ten-point checklist of main methodological problems affecting studies of the effect of mammography screening
programmes on the incidence of advanced breast cancer
Point
#
Issue Problem Consequence Potentially
affected studies
(reference number)
1 Follow-up time The time window available to observe a decrease
(if any) in ABCR is narrow and closes rapidly. In the
Two-County trial, ABCR in the study group began
to decrease 4 years after randomization and
stabilized at a lower level on the 8th year [2].
The ABCR is expected to increase with the
prevalence screening, it may fall in the years
immediately following the prevalence screen,
and will likely be stable at the end of screening
in a cohort of women. In trend and dynamic
population analysis, in the absence of an
individual time zero (time at entry), the effect
is confounded and the effect of screening on
ABCR is underestimated. This is particularly
applicable to estimates of annual percent
change.
[8, 12, 13, 19, 34, 37, 41]
2 Exposure time The target population is a dynamic one (but the
same holds true for cohort studies). Because there
is a latency for the effect of screening on ABCR to
take place, at any point in time there are women
(i.e., new quinquagenarians, new immigrants, and
late attendees) with insufficient exposure time.
The effect of screening on ABCR is
underestimated, due to a disproportionate
influence of prevalence screens.
All studies
3 Pace of
implementation
Public health screening programmes are
implemented gradually, in a markedly stepwise
fashion, since large populations are divided in
distinct administrative units each targeted by
an independent local plan of action.
The effect of screening on ABCR is diluted.
Until implementation is completed, there
are women who are diagnosed with breast
cancer before being invited, and who
greatly contribute to ABCR.
[8, 14, 15, 19, 29, 30,
32, 33, 36–39, 44]
4 Prevalence
effect
The prevalence screen may be associated with
a transient increase in ABCR [13].
During a stepwise implementation of the
programme, when the time elapsed from
the start is theoretically sufficient to see a
decrease in ABCR, this is counteracted by
an opposite effect due to newly enrolled
women – especially if invitations increase
over time.
[8, 14, 15, 19, 29, 30,
32, 33, 36–39, 44]
5 Reference
incidence (i)
The reference (or underlying) incidence rate,
with which to compare the rate observed after
the introduction of screening, is not known
with precision [49].
The rate can be estimated using the rate
observed in the last few years before
screening, assuming its stability over time,
or by linear extrapolation of a pre-existing
trend. The second approach is arguably
preferable, but both are dependent on
underlying assumptions about trends or
absence of trends in incidence, and results
can vary depending on these assumptions.
All studies
6 Reference
incidence (ii)
Whatever incidence rate is being used as a
reference, its validity decreases with increasing
number of years of observation due to
uncontrollable changes (or in the pace of
such changes) in the underlying risk of
breast cancer.
Assessing the long-term effect of screening
on ABCR is subject to considerable
uncertainty and there is potential for
inaccuracy in either direction
(overestimation or underestimation
of effect).
[8, 12, 13, 19, 34, 37, 41]
7 Definition of
advanced
cancer
There is no agreed definition of advanced
breast cancer [50], even though there is general
agreement that large or metastatic cancers are
‘late stage’.
The definition is chosen based on differing
criteria. The pT information alone, which is
the most available one, is direct and relatively
unaffected by biases due to confounding.
Conversely, multiple-stage data are more
meaningful, since the effect of screening
may differ across different categories of
advanced cancers.
All studies
8 Stage
migration
The introduction of sentinel lymph node biopsy
between mid-1990s and mid-2000s caused a
substantial increase in the registered incidence
of node-positive breast cancer (stage migration
bias) [18].
The use of pN staging is problematic in
studies of trends in ABCR over the last
two decades, since changes in the risk of
node-positive cancer cannot be adjusted
for stage migration. The increase in node-
positive disease is likely to be population-
specific and will depend on the rate of
change of local surgical policy. However,
reductions in node-positive disease as a
[12–14, 19, 29–43]
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other reasons (no data for age group 50–69 (n = 2), no
tumour stage data (n = 1), not European Union (n = 1),
and no original data (n = 1)).
Study generalities
These are shown in Additional file 1: Table S1. The 22 eli-
gible studies were from Norway (n = 5), Italy (n = 5), the
Netherlands (n = 4), Denmark (n = 2), Sweden, Finland,
Germany, United Kingdom (UK), Ireland, and France.
There were 9 nation-wide studies, four from Norway
[19, 36, 38, 39], two from the Netherlands [14, 41], two
from Denmark [8, 37], and one from Finland [34].
Programme characteristics
In most studies, the target age range was 50–69 years [8,
14, 15, 19, 29, 30, 32, 35–41, 44] or wider [12, 31, 43].
The papers from Finland, the West Midlands region of
the UK, and Ireland reported programmes aimed at
women aged 50–59 years [34] and 50–64 years [13, 42].
The target age of the Swedish programme varied locally
between 40 and 74 years [33]. The size of the target
population, often not reported, was between 500,000
and 1,000,000 in the national Dutch study [14], in the
Danish studies [8, 37] and in one Italian study [15], and
exceeded 1,000,000 in the study from Sweden [33] and
in a second study from Italy [32]. The screening interval
was 24 months except in the West Midlands (36 months)
[13]. The start of screening programmes ranged from
the early/mid 1970s in Florence, Utrecht, and Nijmegen
[14, 29] to 2005 in the Münster district (Germany) [40].
The time period of observation of breast cancer inci-
dence was between the second half of 1980s and the first
half of the current decade in most studies.
Study design
The methods of analysis varied from the provision of
purely descriptive information to the evaluation of the
magnitude and statistical significance of observed
changes in ABCR. We assigned the design of the studies
that evaluated the magnitude of effect to four broad
categories:
(1) comparison of ABCR before and after the
introduction of screening using different endpoints,
i.e., annual percent change (APC), percent
reduction in ABCR, absolute reduction in ABCR,
incidence rate ratio (IRR), relative risk (RR), excess
RR, slope value calculated from a log-linear Poisson
regression model, and observed:expected ratio, or
simply by juxtaposition of rates [8, 12, 15, 19, 29,
30, 32–40, 43, 44];
(2) comparison of ABCR between each year after the
introduction of screening and the prescreening
years using the estimated annual percent change
(EAPC) [14, 31];
(3) calculation of the EAPC after the introduction of
screening without information on prescreening
years [13, 41]; and
(4) comparison of ABCR in an invited population vs. a
neighbouring uninvited one using the percent
Table 1 Ten-point checklist of main methodological problems affecting studies of the effect of mammography screening
programmes on the incidence of advanced breast cancer (Continued)
Point
#
Issue Problem Consequence Potentially
affected studies
(reference number)
results of screening are likely to be
underestimated rather than overestimated
due to the stage migration.
9 Missing data on
tumour stage
Whatever staging system is being used, the
introduction of a screening programme tends
to bring an improved quality of breast cancer
registration, with a sharp decrease in the
proportion of unknown-stage cancers.
Because more cases are increasingly placed
in all known-stage categories, an apparent
increase in all stage-specific rates occurs –
including ABCR.
[8, 15, 30, 32, 33, 38, 39]
10 Statistical
approach
The statistical approach is not standardised,
and includes the provision of purely
descriptive information and the use of
methods which are difficult to interpret,
such as joinpoint analysis.
Descriptive information does not allow
evaluation of the magnitude and significance
of observed changes in ABCR. Methods like
the joinpoint analysis are useful for assessing
the points in time when ABCR begins to
decrease and when it stabilizes, but may
be misleading when used to assess the
significance of the trend. Also, the
important issue is arguably what happened
to ABCR following the screening rather
than at what point a change occurred
in the direction of a trend, which is
affected by both confounding and
analytic assumptions.
[8, 12, 13, 19, 29,
35, 40–43]
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reduction in ABCR. This is the case for a single
study [42], although the inclusion of neighbouring
nonscreening areas is a secondary part of the design
of other investigations [8, 36].
The statistical significance of observed changes, if any,
was assessed in 17 studies [8, 13–15, 30–34, 36–41, 43, 44].
Some information on the trend (before and after the
introduction of screening) for the frequency of
unknown-stage cancer was provided by 11 studies [8, 12,
15, 19, 29, 30, 32, 33, 35, 38, 39]. The tumour staging
criteria varied. Although 20 studies used the UICC
TNM classification, there was little agreement in the
definition of advanced breast cancer. In one study,
incidence was presented for multiple stage categories
but the advanced category (or categories) was not expli-
citly identified [29].
Study results
A significantly favourable impact on ABCR was reported
by nine studies. In the national Dutch study, ABCR [T2
+ with lymph node (N+) and/or distant metastases
(M1)] decreased by 12% [14]. In one regional Dutch
study, the annual IRR varied between 0.86–0.82 (T2+
cancer) and 0.83–0.72 (N+ cancer) [31]. In the study
from Sweden, RRs were 0.74 (tumour size > 2 cm), 0.89
(N+ cancer), and 0.84 (Stage II+ cancer) [33]. In the
national Finnish study, the ABCR (non-localised cancer)
decreased by 9% [34]. A significant impact on ABCR
was observed in three studies from Italy. Paci et al.
Fig. 2 Flowchart of search strategy and selection of papers
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found a RR (Stage II+) of 0.72 [30]. The figure reported
by Foca et al. for T2+ cancer was between 0.81–0.71
[15]. A secondary observation from a more recent Italian
cohort study comparing attenders and non-attenders
was a significant ratio of 0.83 between the observed
number of T2+ cancers in a whole invited cohort and
the expected number based on pre-screening rates [44].
In a large French study, the decrease was significant
both for T2+ cancer and Stage II+ cancer [43]. In a local
study from Germany, Simbrich et al. demonstrated sig-
nificant decreases of varying magnitude in annual ABCR
among women aged 50–69 years [40].
Two studies provided unclear results. A Danish study
described a transient increase in incidence of cancers >
20 mm in size in early screening regions followed by a de-
cline of N+ cancers in late screening regions [37]. The
Italian study of Buiatti et al. was limited to ≤3 screening
years for most of the participating subareas. After early
significant increases in T2+ cancer rates in two of them, a
moderate reduction was observed 4–6 years after the start
of the programme in the area with longer follow-up [32].
Four nationwide Norwegian studies reported contra-
dictory findings. Kalager et al. observed a significant IRR
(Stage III+ cancer) of 0.76, but the same figure was
found in the not-yet invited population before screening
[36]. Also, the reduction was confirmed by a second
study but in association with an increase for Stage II
cancer [39]. Others reported the opposite, that is, a de-
crease for Stage II cancer and an increase for Stage III
cancer [19]. Another study found significant increases
both for Stage II and Stage III cancers and a decrease
for Stage IV cancer alone [38]. None of these studies
used individual data indicating whether women were di-
agnosed before or after they were invited to participate.
In addition to the abovementioned studies from
France [43] and Germany [40], three investigations used
the joinpoint analysis or the Poisson regression analysis.
In the West Midlands (UK), the incidence of N+ cancer
increased in the first years of screening and then
returned to the baseline level but with a significant posi-
tive APC of 1.1 [13]. In Denmark, the negative APC in
incidence of T2+ cancer was significant but the ratio be-
tween post-screening and pre-screening rate was not sig-
nificantly different from the unity [8]. In another study
from the Netherlands, a non-significant negative APC in
Stage 2+ cancer rate was observed but the estimate in-
cluded the whole of women aged 50 or older [41].
Four studies, in addition to one of the abovementioned
Norwegian studies [19], presented no assessment of sig-
nificance of observed changes in ABCR (if any). One
Italian study reported a 8.7% decrease for N+ cancer
[29]. In the fifth Norwegian study, ABCR (regional or
distant cancer) rose before the introduction of screening,
and fluctuated thereafter at levels that were generally
above the last pre-screening level [35]. In a regional
Dutch study, ABCR (Stage IIA+ cancer) was described
to be stable before and after the introduction of scree-
ning [12]. In Ireland, ABCR (Stage 2+) in a region
targeted by screening in 2000 fell by 20% in comparison
with a region in which screening was implemented only
seven years later [42].
Method check
The right-hand column in Table 1 gives the results of
the review of selected papers against the ten-point
checklist.
The issue of follow-up time (#1) is related to the short
time window after prevalence screening where a decrease
in ABCR can be observed. Studies with a long time win-
dow, most notably seven studies [8, 12, 13, 19, 34, 37, 41]
in which the time difference between the year of start of
the screening programme and the last year of observation
was ≥15 years, will not be able to show this decrease. This
is particularly problematic when interpreting annual
percent changes [13, 41]. If screening is working as antici-
pated, annual percent changes will be substantial in the
first years of a programme, but will be small or absent
after the programme has achieved widespread coverage as
the new lower incidence will be roughly constant. The
related problem of the effect of a dynamic population
on exposure time (#2) applies to all studies. Foca et
al. excluded women aged 50–54 years but not new
immigrants and late attendees [15]. Anttila et al. pro-
vided separate data for women aged 50–54 years and
55 years or older [34].
The problem due to pace of implementation (#3) ap-
plies especially to the Swedish study [33], the Italian
studies [15, 29, 30, 32, 44], the nationwide Norwegian
studies [19, 36, 38, 39], the Danish studies [8, 37], and
the nationwide Dutch study [14]. In fact, it is rare that a
mammography service screening programme is started
simultaneously throughout a large geographic area. In
two of these studies, there was explicit adjustment of the
analysis to address this issue. In the Swedish study, the
first screening years in some counties were omitted from
analysis because mammography coverage, or the level of
exposure, was still low [33]. In addition, in this study, in-
dividual data on screening exposure was available for the
nominal screening period. In the study of Foca et al. the
years of observation were synchronised at the municipa-
lity level, and those municipalities where saturation was
not reached within a short (arbitrary) time interval were
not taken into consideration [15]. This proved to be a
practical but powerful approach to account for gradual
programme implementation. In other studies, at least
some information was available for the reader to assess
the potential size of the problem. The papers reporting
the nationwide Dutch study and the Danish study drew
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the reader’s attention to this issue by presenting results
for individual years and for regions implementing
screening at different times [14, 37]. One of the Italian
studies also had individual data on screening exposure
during the nominal screening period [30].
The prevalence effect problem (#4) applies virtually
to all studies with markedly stepwise implementation
of the programme. Of the two problems concerning
the reference incidence, the inevitable lack of a
verifiable estimate of the underlying background in-
cidence rate (#5) applies to all studies. Outside of a
randomised trial, the estimation cannot be performed
without assumptions regarding the likely incidence
of breast cancer, and specifically late stage breast
cancer, in the absence of screening. The problem of
its decreasing validity over time (#6) applies espe-
cially to those studies, already mentioned above, in
which the time interval between the last prescreen-
ing year and the last year of observation was
≥15 years [8, 12, 13, 19, 34, 37, 41]. However, again,
presentation of data for individual years affords the
reader a means of assessing the likely extent of
underestimation [37].
Difficulties with the definition of advanced cancer (#7)
apply to all studies, because all such definitions have
pros and cons. Some used the pT information alone [8,
15, 44], others used multiple advanced stage definitions
with separate results [13, 19, 29, 31, 33, 36–39, 43], or a
single definition of advanced stage based on the TNM
system [12, 14, 30, 32, 34, 35, 40–42].
Of the two problems concerning tumour stage in-
formation, the problem of stage migration (#8) applies
to all studies except those where the definition of ad-
vanced cancer was exclusively based on pT informa-
tion [8, 15, 44]. More than half of the studies did not
take changes in the proportion of unknown stage in-
formation (#9) into consideration, providing no trend
in missing tumour stage data [12–14, 31, 34, 36, 37,
40–44] or only very partial data [32]. A stable trend
was reported by one of the Italian studies [29]. A per-
cent decrease of incident breast cancers with missing
stage information was observed in other two Italian
studies [15, 30], in the Swedish study [33], in three
Norwegian studies [35, 38, 39], and in a study from
Denmark [8]. In two of these, the resulting bias was
adjusted for in the design [15] and, respectively, in
the analysis [33].
Finally, the problem of a lack of standardised statistical
approach (#10) applies especially to those studies report-
ing purely descriptive data [29, 35, 42] or incidence
curves without numerical data [12, 19] and those based
on the joinpoint analysis [13, 41] and the Poisson regres-
sion analysis [8, 40, 43], the results of which are difficult
to interpret.
Discussion
The 22 studies included in this review showed consider-
able variation in results on the estimated effect of the
introduction of population-based mammography screen-
ing programmes on the ABCR. Of note, there are four
circumstantial indications that the overall effect of meth-
odological issues resulted in an underestimation of the
impact on ABCR: first, most biases have a conservative
direction (#2, #3, #4, #8, and #9); second, most of the
largest studies reported a significant decrease in ABCR
[14, 15, 33, 44]; third, the decrease was more pro-
nounced after some adjustments for design biases were
made [15, 33]; and, fourth, taking the entire series of
studies into consideration, nine of them found a signifi-
cant, albeit varying, reduction in ABCR. They represent
the majority of published studies once those affected by
critical limitations are excluded. In our opinion, the re-
port by Buiatti et al. [32], focusing the first 3 years of
screening, and the four nationwide Norwegian studies
[19, 36, 38, 39], with their conflicting and partly opposite
findings, are difficult to interpret. Furthermore, the study
by Larsen et al. demonstrated clearly that stage-specific
incidence of breast cancer in Norway was influenced by
changes in coding and classification practices, which
makes it even more challenging to evaluate and compare
stage-specific trends and stage migration of breast can-
cer by age and time [19].
Nonetheless, the conclusions of the available litera-
ture still warrant careful interpretation, because not
all methodological concerns could be avoided. Also,
while the direction of the potential biases can be
predicted, it is difficult and sometimes impossible to
estimate their magnitude. Some of the problems are
unavoidable and apply to all studies (specifically #2,
#5, #7), whereas others could potentially be addressed
in the design phase. In any case, it would be arbitrary
to rank their consequences in terms of relative impact
on study results, which may also vary in relation to
local contingencies. More realistically, we aimed at
summarising the challenges in designing studies on
ABCR in order to improve consistency in the repor-
ting of results.
Ideally, the study population should be rapidly
saturated by exposure to screening, and this should take
less time than that needed for the expected effect on
ABCR to become apparent. From this point of view
population-based service screening programmes often
cannot provide this ideal situation. The dynamic nature
of the target populations, together with the phased
introduction of most screening programmes and the fact
that the prevalence screen will be associated with an
increase in ABCR, will lead to an underestimate of the
decrease in ABCR, as will the reduction in the propor-
tion of unknown-stage tumours.
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In addition, certain statistical analyses, such as the join-
point analysis (#10), may generate false-negative results.
Conversely, problems of estimation of underlying incidence
in the absence of screening, and particular definitions of
advanced stage (#5 and #7) may have been responsible for
unpredictable effects in either direction. Many of the prob-
lems also arise from the reliability and validity of incidence
data, in particular the unavailability of reliable reference inci-
dence rates for advanced cancer, especially in a historical
comparison period, together with the sharp decrease in the
proportion of unknown-stage cancers following the intro-
duction of screening. Stage migration bias, caused by the
implementation of sentinel lymph node biopsy between the
mid-1990s and mid-2000s [18, 19], will also have had an
impact.
Furthermore, the inconsistency in the definition of ad-
vanced cancer gives rise to difficulties in interpreting the
collected evidence. There is a possibility of a residual im-
provement within stage categories, but this is more diffi-
cult to demonstrate. The consistency between studies in
the use of tumour diameter, stage and other parameters
was limited. Another limitation in the classification of ad-
vanced cancers, especially in studies performed nowadays,
is the variation among cancer registries (and within cancer
registries over time) in what clinical and pathological data
they collect. There is growing interest in the effect of
screening, if any, on biological and molecular markers,
but it will be some time before sufficient data are gener-
ated to answer this question. Incidentally, we believe that
deficiencies in staffing, organisation, access, and funding
of ongoing mammography service screening programmes
warrant much greater consideration in the debate about
their effectiveness.
From a scientific point of view, however, the most severe
limitations of reviewed studies (#1 to #4) affected the
study design. The main departures from the ideal design
of a temporal correlation study were the following. First,
as shown in the Swedish Two-County trial [2, 15], the
time window available to observe an impact (if any) on
ABCR closes rapidly. In populations where screening has
been ongoing for a longer time [12, 13, 41], analysis
should focus on establishing whether incidence of ad-
vanced disease is lower than before, not ‘still decreasing’.
The misuse of the joinpoint analysis and of the Poisson re-
gression analysis (#10) is itself related to the assumption
that the downward incidence trend must continue indef-
initely [13]. This cannot be the case, unless a substantial
increase of mammography sensitivity occurs over time.
Second, the 3-year latency of the effect of screening on
ABCR means that, in the dynamic target population of a
service screening programme, at any point in time, there
is always a subset of women with an exposure time to
screening that is too short to have an effect on the risk of
advanced breast cancer. Third, and more important,
service screening programmes in Europe were introduced
very gradually. This inevitably caused the same dilution of
effects as that historically described for cervical cancer
screening in Denmark and Norway as compared with
Finland and Sweden [34].
In fairness, most of the studies reviewed either attempted
to control for possible problems by adjustment in statistical
analysis or presented data in sufficient detail for the reader
to judge the likely presence and direction of potential
biases. There have been surprisingly few attempts, on the
other hand, to adjust the design to minimise biases. The
only previous literature review on ABCR following the
introduction of mammography screening programmes did
not take into consideration the limitations of published arti-
cles, except for the stage migration bias [5, 19]. The authors
concluded that trends in advanced breast cancer incidence
do not support a role for screening in the decrease in
mortality. The present work demonstrates that the available
literature cannot support such a conclusion, and indeed
supports the opposite.
Conclusions
In summary, all studies were challenged by multiple is-
sues, although to a varying extent. The trend in most of
evaluable results, even though inconsistent, does support
a reduction in advanced breast cancer incidence follo-
wing the introduction of mammography screening. In
view of the impact on ABCR observed in RCTs [1], we
conclude that much of the current controversy on
mammography service screening programmes is due to
observational data that were gathered and/or analysed
with methodological approaches which could not cap-
ture stage effects in full [27, 28]. Notwithstanding this
fact, changes in ABCR remain an important early indica-
tor of effectiveness. Improving the knowledge of limita-
tions in previous studies will help to establish consensus
on the correct methodology. The development of more
robust and empirically driven techniques should take
into account both the practical implementation of
cancer screening activities and the evaluation of their ef-
fects. This will enable a better fit of the design of studies
on ABCR to the particular context of a mammography
service screening programme.
Appendix
Search strategy
(((((((((cancer stage[All Fields] OR cancer stages[All
Fields] OR cancer staging[All Fields]))
OR (metastases)) OR (lymph nodes)) OR (lymphatic
metastases)) OR (lymph nod*)) OR (tnm stage)) OR
(tnm stag*))) AND (((((((early detection of breast
cancer)) OR (population screen*)).
OR (mass screen*)) OR (mammogr*)) OR (cancer
mass screening)) OR (mammography))
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Additional file
Additional file 1: Table S1. Characteristics of the screening
programmes, and design and results of studies of the impact of
mammography screening on the incidence of advanced breast cancer.
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